JPMorgan raised the firm’s price target on AstraZeneca (AZN) to 16,000 GBp from 14,000 GBp and keeps an Overweight rating on the shares. JPMorgan also added AstraZeneca to its European Analyst Focus List. The firm adjusted ratings in the European pharma group as part of its 2026 outlook. It expects sector performance to be driven by pipeline readouts, saying much of the concern around the impact of U.S. price pressure on sector earnings has dissipated in Q4. JPMorgan downgraded companies with a lack of pipeline readouts in 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
- Salesforce (CRM) Wins AstraZeneca Deal, Becomes the Unified Global Platform
- Salesforce’s Agentforce selected by AstraZeneca as unified global platform
- AstraZeneca Stake Adjustment by Capital Group
- FDA shift in drug study requirements sends trial runners lower